These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 32484754)

  • 21. Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
    Olson R; Jiang W; Liu M; Bergman A; Schellenberg D; Mou B; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Chng N; Matthews Q; Baker S; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresene S; Tyldesley S
    JAMA Oncol; 2022 Nov; 8(11):1644-1650. PubMed ID: 36173619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer.
    Kumar A; Straka C; Courtney PT; Vitzthum L; Riviere P; Murphy JD
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1185-1194. PubMed ID: 33002541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
    Phillips R; Shi WY; Deek M; Radwan N; Lim SJ; Antonarakis ES; Rowe SP; Ross AE; Gorin MA; Deville C; Greco SC; Wang H; Denmeade SR; Paller CJ; Dipasquale S; DeWeese TL; Song DY; Wang H; Carducci MA; Pienta KJ; Pomper MG; Dicker AP; Eisenberger MA; Alizadeh AA; Diehn M; Tran PT
    JAMA Oncol; 2020 May; 6(5):650-659. PubMed ID: 32215577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
    Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
    Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic Ablative Radiotherapy for Gynecological Oligometastatic and Oligoprogessive Tumors.
    Donovan EK; Lo SS; Beriwal S; Chen H; Cheung P; Keller A; Nwachukwu C; Mantz C; Pond GR; Schnarr K; Swaminath A; Albuquerque K; Leung E
    JAMA Oncol; 2024 Jul; 10(7):941-948. PubMed ID: 38869888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
    Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
    PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies.
    Mesko S; Sandler K; Cohen J; Konecny G; Steinberg M; Kamrava M
    Int J Gynecol Cancer; 2017 Feb; 27(2):403-408. PubMed ID: 27870704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic radiotherapy in oligometastatic cancer.
    Kennedy TAC; Corkum MT; Louie AV
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial.
    Schellenberg D; Gabos Z; Duimering A; Debenham B; Fairchild A; Huang F; Rowe LS; Severin D; Giuliani ME; Bezjak A; Lok BH; Raman S; Chung P; Zhao Y; Ho CK; Lock M; Louie AV; Lefresne S; Carolan H; Liu M; Yau V; Ye A; Olson RA; Mou B; Mohamed IG; Petrik DW; Dosani M; Pai H; Valev B; Gaede S; Warner A; Palma DA
    Int J Radiat Oncol Biol Phys; 2025 Jan; 121(1):28-38. PubMed ID: 39168356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.
    Comito T; Cozzi L; Clerici E; Campisi MC; Liardo RL; Navarria P; Ascolese A; Tozzi A; Iftode C; De Rose F; Villa E; Personeni N; Rimassa L; Santoro A; Fogliata A; Mancosu P; Tomatis S; Scorsetti M
    BMC Cancer; 2014 Aug; 14():619. PubMed ID: 25163798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II).
    Siva S; Kron T; Bressel M; Haas M; Mai T; Vinod S; Sasso G; Wong W; Le H; Eade T; Hardcastle N; Chesson B; Pham D; Høyer M; Montgomery R; Ball D
    BMC Cancer; 2016 Mar; 16():183. PubMed ID: 26944262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis.
    Lehrer EJ; Singh R; Wang M; Chinchilli VM; Trifiletti DM; Ost P; Siva S; Meng MB; Tchelebi L; Zaorsky NG
    JAMA Oncol; 2021 Jan; 7(1):92-106. PubMed ID: 33237270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
    Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
    Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer.
    Doyle E; Killean AJ; Harrow S; Phillips ID
    Radiother Oncol; 2024 Jul; 196():110288. PubMed ID: 38648995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer.
    Wijetunga NA; Dos Anjos CH; Zhi WI; Robson M; Tsai CJ; Yamada Y; Dover L; Gillespie EF; Xu AJ; Yang JT
    Cancer Med; 2021 Aug; 10(15):5163-5174. PubMed ID: 34159748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
    Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
    Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer.
    Mercier C; Claessens M; De Troyer B; Debacker T; Fransis K; Vandeursen H; Ost P; Dirix P
    Front Oncol; 2022; 12():863609. PubMed ID: 35494057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereotactic Ablative Radiation Therapy for Pulmonary Recurrence-Based Oligometastatic Non-Small Cell Lung Cancer: Survival and Prognostic Value of Regulatory T Cells.
    Liu C; Sun B; Hu X; Zhang Y; Wang Q; Yue J; Yu J
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1055-1064. PubMed ID: 31437470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.